Butyrophilin subfamily 2 member A2 (BTN2A2)

Butyrophilin subfamily 2 member A2 (BTN2A2) is a type I transmembrane glycoprotein and a member of the butyrophilin family, structurally classified within the immunoglobulin superfamily and related to the B7 family of immunoregulatory molecules. BTN2A2 is broadly expressed on antigen-presenting cells and functions as an immune coinhibitory molecule that fine-tunes T-cell activation, proliferation, and cytokine secretion, primarily by inhibiting both CD4+ and CD8+ T cell responses. It promotes the induction of regulatory T cells and maintains immune homeostasis, with deletion studies in mice demonstrating the critical role of BTN2A2 in preventing autoimmunity and sustaining tolerance. BTN2A2 is transcriptionally regulated by CIITA and RFX and shares functional properties with other butyrophilins. While it is not currently targeted by approved therapeutic agents, BTN2A2 represents a plausible checkpoint for immune modulation in cancer and autoimmune diseases

Other names

BTN2A2BT2.2BTF2BTN2.2Butyrophilin 2Butyrophilin subfamily 2 member A2

Hypothetical: Modulation of BTN2A2 would likely inhibit or potentiate T-cell activation and proliferation, possibly impacting immune tolerance and autoimmunity; drugs engaging BTN2A2 could act as agonists or antagonists to modulate T-cell responses (but no agents currently in use or clinical development reported in available literature). Main mechanism in nature: Cell-surface ligand/receptor coinhibition for dampening T-cell activation via transcriptional regulation, immune checkpoint function